# Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification

Study · id `cardio:ct-nct02066662` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02066662](<https://clinicaltrials.gov/study/NCT02066662>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02066662

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 192 participants.

## Technical summary

Registry record NCT02066662. Randomized; single masking; primary purpose basic science. Start 2013-07 (registry gives no type); primary completion 2020-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose basic science
- Phase: Phase 4
- Enrolled: 192 participants (enrolled count; ClinicalTrials.gov record NCT02066662, source copy `cardio:ctgov-nct02066662-2020-10-22`, retrieved 2026-10-26)
- Start date: 2013-07 (registry gives no type) (ClinicalTrials.gov record NCT02066662, source copy `cardio:ctgov-nct02066662-2020-10-22`, retrieved 2026-10-26)
- Primary completion: 2020-03 (actual) (ClinicalTrials.gov record NCT02066662, source copy `cardio:ctgov-nct02066662-2020-10-22`, retrieved 2026-10-26)
- Completion: 2020-03 (actual) (ClinicalTrials.gov record NCT02066662, source copy `cardio:ctgov-nct02066662-2020-10-22`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT02066662, source copy `cardio:ctgov-nct02066662-2020-10-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02066662-2020-10-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
- Condition: Atrial Fibrillation or Pulmonary Embolism
- Condition: Need of Long Term Oral Anticoagulation Therapy (OAT)
- Condition: Existent Coronary or Valvular Calcification, or Both and Agatston Score &gt; 50 in at Least One Location
- Intervention (Drug): Rivaroxaban or Marcumar
- Lead sponsor: RWTH Aachen University
- Lead sponsor class: OTHER
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: RWTH Aachen University (`cardio:org-rwth-aachen-university`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

## Provenance

Content hash: ad7deb9a9ce07874955dc5e05109b3289f8f22e0b8ffd6a512fae10a7b53ae06
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
